Prognostic significance of the s-phase fraction of light-chain- restricted cytoplasmic immunoglobulin (clg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486

M. C. Trendle, T. Leong, R. A. Kyle, J. A. Katzmann, M. M. Oken, Neil Elliot Kay, B. G. Van Ness, Philip R. Greipp

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The bone marrow plasma cell labeling index (PCLI) as measured by bromodeoxyuridine uptake is a well-established independent prognostic factor for patients with newly diagnosed multiple myeloma, but the test is not easily done in most laboratories. The purpose of this study was to determine if the proliferative activity (% S-phase) as determined by two-color flow cytometry for cytoplasmic immunoglobulin (clg) light chain and DNA content also had prognostic significance. As part of Eastern Cooperative Oncology Group clinical trial E9486, 500 patients had successful performance of the bone marrow PCLI. Of 349 patients who had flow clg and DNA content cytometry, 210 had adequate data to reliably calculate S-phase %. Patients with low % S- phase fraction (<2%) had a significant overall survival advantage over patients high % S-phase fraction (≥2%), median survivals 4.1 vs. 2.9 years (P = 0.032). Measurement of the S-phase % by flow cytometry gives significant prognostic information in patients with newly diagnosed myeloma. However, in multivariate analysis, S-phase % did not add prognostic information when PCLI was in the model. S-phase % added prognostic information only when all cases with flow measurement of S-phase % were included, and when PCLI was excluded from the model. Discriminating a population of only clg positive cells proved difficult in patients with a low percentage of bone marrow plasma cells. Methodology to measure S-phase % in patients with a low percent plasma cells is needed before this technique can be used for diagnosis and prognosis in myeloma.

Original languageEnglish (US)
Pages (from-to)232-237
Number of pages6
JournalAmerican Journal of Hematology
Volume61
Issue number4
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Plasma Cells
Multiple Myeloma
S Phase
Immunoglobulins
Light
Bone Marrow Cells
Therapeutics
Flow Cytometry
Immunoglobulin Light Chains
Survival
DNA
Bromodeoxyuridine
Multivariate Analysis
Color
Clinical Trials
Population

Keywords

  • Flow cytometry
  • Labeling index
  • Multiple myeloma
  • S-phase

ASJC Scopus subject areas

  • Hematology

Cite this

Prognostic significance of the s-phase fraction of light-chain- restricted cytoplasmic immunoglobulin (clg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486. / Trendle, M. C.; Leong, T.; Kyle, R. A.; Katzmann, J. A.; Oken, M. M.; Kay, Neil Elliot; Van Ness, B. G.; Greipp, Philip R.

In: American Journal of Hematology, Vol. 61, No. 4, 1999, p. 232-237.

Research output: Contribution to journalArticle

@article{5694ea84c43f4cf8b6643aa3c77f9827,
title = "Prognostic significance of the s-phase fraction of light-chain- restricted cytoplasmic immunoglobulin (clg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486",
abstract = "The bone marrow plasma cell labeling index (PCLI) as measured by bromodeoxyuridine uptake is a well-established independent prognostic factor for patients with newly diagnosed multiple myeloma, but the test is not easily done in most laboratories. The purpose of this study was to determine if the proliferative activity ({\%} S-phase) as determined by two-color flow cytometry for cytoplasmic immunoglobulin (clg) light chain and DNA content also had prognostic significance. As part of Eastern Cooperative Oncology Group clinical trial E9486, 500 patients had successful performance of the bone marrow PCLI. Of 349 patients who had flow clg and DNA content cytometry, 210 had adequate data to reliably calculate S-phase {\%}. Patients with low {\%} S- phase fraction (<2{\%}) had a significant overall survival advantage over patients high {\%} S-phase fraction (≥2{\%}), median survivals 4.1 vs. 2.9 years (P = 0.032). Measurement of the S-phase {\%} by flow cytometry gives significant prognostic information in patients with newly diagnosed myeloma. However, in multivariate analysis, S-phase {\%} did not add prognostic information when PCLI was in the model. S-phase {\%} added prognostic information only when all cases with flow measurement of S-phase {\%} were included, and when PCLI was excluded from the model. Discriminating a population of only clg positive cells proved difficult in patients with a low percentage of bone marrow plasma cells. Methodology to measure S-phase {\%} in patients with a low percent plasma cells is needed before this technique can be used for diagnosis and prognosis in myeloma.",
keywords = "Flow cytometry, Labeling index, Multiple myeloma, S-phase",
author = "Trendle, {M. C.} and T. Leong and Kyle, {R. A.} and Katzmann, {J. A.} and Oken, {M. M.} and Kay, {Neil Elliot} and {Van Ness}, {B. G.} and Greipp, {Philip R.}",
year = "1999",
doi = "10.1002/(SICI)1096-8652(199908)61:4<232::AID-AJH2>3.0.CO;2-T",
language = "English (US)",
volume = "61",
pages = "232--237",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Prognostic significance of the s-phase fraction of light-chain- restricted cytoplasmic immunoglobulin (clg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486

AU - Trendle, M. C.

AU - Leong, T.

AU - Kyle, R. A.

AU - Katzmann, J. A.

AU - Oken, M. M.

AU - Kay, Neil Elliot

AU - Van Ness, B. G.

AU - Greipp, Philip R.

PY - 1999

Y1 - 1999

N2 - The bone marrow plasma cell labeling index (PCLI) as measured by bromodeoxyuridine uptake is a well-established independent prognostic factor for patients with newly diagnosed multiple myeloma, but the test is not easily done in most laboratories. The purpose of this study was to determine if the proliferative activity (% S-phase) as determined by two-color flow cytometry for cytoplasmic immunoglobulin (clg) light chain and DNA content also had prognostic significance. As part of Eastern Cooperative Oncology Group clinical trial E9486, 500 patients had successful performance of the bone marrow PCLI. Of 349 patients who had flow clg and DNA content cytometry, 210 had adequate data to reliably calculate S-phase %. Patients with low % S- phase fraction (<2%) had a significant overall survival advantage over patients high % S-phase fraction (≥2%), median survivals 4.1 vs. 2.9 years (P = 0.032). Measurement of the S-phase % by flow cytometry gives significant prognostic information in patients with newly diagnosed myeloma. However, in multivariate analysis, S-phase % did not add prognostic information when PCLI was in the model. S-phase % added prognostic information only when all cases with flow measurement of S-phase % were included, and when PCLI was excluded from the model. Discriminating a population of only clg positive cells proved difficult in patients with a low percentage of bone marrow plasma cells. Methodology to measure S-phase % in patients with a low percent plasma cells is needed before this technique can be used for diagnosis and prognosis in myeloma.

AB - The bone marrow plasma cell labeling index (PCLI) as measured by bromodeoxyuridine uptake is a well-established independent prognostic factor for patients with newly diagnosed multiple myeloma, but the test is not easily done in most laboratories. The purpose of this study was to determine if the proliferative activity (% S-phase) as determined by two-color flow cytometry for cytoplasmic immunoglobulin (clg) light chain and DNA content also had prognostic significance. As part of Eastern Cooperative Oncology Group clinical trial E9486, 500 patients had successful performance of the bone marrow PCLI. Of 349 patients who had flow clg and DNA content cytometry, 210 had adequate data to reliably calculate S-phase %. Patients with low % S- phase fraction (<2%) had a significant overall survival advantage over patients high % S-phase fraction (≥2%), median survivals 4.1 vs. 2.9 years (P = 0.032). Measurement of the S-phase % by flow cytometry gives significant prognostic information in patients with newly diagnosed myeloma. However, in multivariate analysis, S-phase % did not add prognostic information when PCLI was in the model. S-phase % added prognostic information only when all cases with flow measurement of S-phase % were included, and when PCLI was excluded from the model. Discriminating a population of only clg positive cells proved difficult in patients with a low percentage of bone marrow plasma cells. Methodology to measure S-phase % in patients with a low percent plasma cells is needed before this technique can be used for diagnosis and prognosis in myeloma.

KW - Flow cytometry

KW - Labeling index

KW - Multiple myeloma

KW - S-phase

UR - http://www.scopus.com/inward/record.url?scp=0032841338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032841338&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8652(199908)61:4<232::AID-AJH2>3.0.CO;2-T

DO - 10.1002/(SICI)1096-8652(199908)61:4<232::AID-AJH2>3.0.CO;2-T

M3 - Article

C2 - 10440908

AN - SCOPUS:0032841338

VL - 61

SP - 232

EP - 237

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -